Journal
CIRCULATION-CARDIOVASCULAR GENETICS
Volume 5, Issue 1, Pages 51-57Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGENETICS.111.960252
Keywords
atorvastatin; simvastatin; coronary heart disease; cardiovascular outcomes; KIF6
Funding
- Fonds de la recherche en sante du Quebec
- Fondation de l'Institut universitaire de cardiologie et de pneumologie de Quebec
- Dutch Heart Foundation
- Pfizer
- Celera
- Abbott
- AstraZeneca
- CSL
- Merck
- Roche
- Sanofi-Aventis
- Aegerion
- Anthera
- Cortria
- InteKrin
- Servier
- Biosante
- Merck Schering-Plough
- Bristol-Myers Squibb
Ask authors/readers for more resources
Background-Carriers of the KIF6 719Arg variant may be at increased risk for CVD and may benefit more from statin therapy, in terms of CVD risk reduction, than noncarriers. Our objective was to investigate whether carriers of the KIF6 719Arg genetic variant (rs20455) are at increased cardiovascular risk and obtain more benefit from high-dose statin therapy than do noncarriers. Methods and Results-We used an adjusted Cox proportional hazard model to assess the hazard ratio (HR) for the reduction of major cardiovascular events by 80 mg/d atorvastatin over 10 mg/d atorvastatin in 4599 patients of the Treating to New Targets (TNT) study and by 80 mg/d atorvastatin over 20-40 mg/d simvastatin in 6541 patients of the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) study. A total of 381 and 648 patients had a cardiovascular event during follow-up in TNT and IDEAL, respectively. Heterozygotes and homozygotes for the minor allele were not at increased risk compared with noncarriers. In TNT, for noncarriers of the 719Arg allele, the HR for high-versus low-dose atorvastatin was 0.81 (95% confidence interval, 0.59-1.11). In carriers of 1 or 2 minor alleles, the HR was 0.85 (0.66-1.11) and carriers of 2 copies of the minor allele obtained a significant risk reduction (HR: 0.44, 95% confidence interval, 0.23-0.84). In IDEAL, the respective HRs were 0.85 (0.67-1.10), 0.88 (0.62-1.07) and 0.91 (0.58-1.43). The interaction term for carrier status by treatment was also nonsignificant (P = 0.810 in TNT and P = 0.909 in IDEAL). Conclusions-In these 2 large, randomized clinical trials, carriers of the KIF6 719Arg allele were not at increased cardiovascular risk and did not obtain consistent cardiovascular benefit from high-dose statin therapy compared with noncarriers. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00327691. (Circ Cardiovasc Genet. 2012;5:51-57.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available